Neratinib has a synergistic antitumor effect with everolimus in PIK3CA-mutated HER2+ breast cancer patient-derived xenograft models and with trametinib in HER2-mutated HER2+ breast cancer patient-derived xenograft models [27]. The gene discussed is PIK3CA; the disease is breast carcinoma.